-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie’s ABBV-466 shows higher endoscopic remission rates than monotherapies in Phase 2a Crohn’s trial

PUBT·10/19/2026 08:02:15
Listen to the news
AbbVie’s ABBV-466 shows higher endoscopic remission rates than monotherapies in Phase 2a Crohn’s trial
  • AbbVie’s investigational ABBV-466 outperformed either monotherapy in achieving endoscopic remission in a Phase 2a trial for moderate to severe Crohn’s disease.
  • The treatment advantage widened by Week 24 in the 300-patient TARGET-CD study.
  • Serious adverse events were comparable across treatment groups.
  • Results will be presented October 19, 2026, at the United European Gastroenterology Week Congress in Barcelona.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610190400PR_NEWS_USPR_____CG74671) on October 19, 2026, and is solely responsible for the information contained therein.